PubMed · 7968760
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
W J Louis, S N Louis, H Krum. 1994-11-07. Beta-blockers.. https://doi.org/10.5694/j.1326-5377.1994.tb127604.x
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
Surfactants suppress the electrospray ionization (ESI) of various compounds. Here we demonstrate that fluorinated surfactants such as perfluorooctanoic acid (PFOA) and perfluorooctanesulfonic acid (PFOSA) could be employed for ESI-MS without a significant decrease in sensitivity. Both PFOA and PFOSA could be applied to the analysis of ionic and nonionic compounds by micellar electrokinetic chromatography (MEKC)/ESI-MS, although the migration window was limited. Furthermore, in HPLC/ESI-MS, PFOA could function as a paired ion for enzymatically digested peptides as well as sulfonamides and significant effects of PFOA on the signal peak shape, retention times, and sensitivity of the analytes were observed compared to those of trifluoroacetic acid or sodium dodecyl sulfate (SDS). In addition, PFOA was applied to protein analysis by ESI-MS, and superior sensitivity was noted, compared to other surfactants such as octylglucoside, dodecylglucoside, and SDS. Although 21% of the original signal was observed in the presence of 1% PFOA, this surfactant could be easily removed by evaporation, which resulted in the recovery of 96% of the original signal. Because these fluorinated surfactants could also be used for solubilization, extraction, and disaggregation of proteins, they should greatly expand the applicability of the ESI-MS to the biological problems of proteins.
Explore the source record for details and available documents.
BACKGROUND: Ischemic preconditioning (PC) represents a state-of-the-art technique for myocardial preservation. Although certain intracellular mediators have been shown to play a role in PC, the exact nature of the trigger for PC is not known. Our previous study demonstrated that intracellular bradykinin released from the heart during ischemia/reperfusion plays a role in myocardial preservation. This study was undertaken to further examine the mechanism of bradykinin-mediated PC. METHODS AND RESULTS: Since the bradykinin B(2) receptor is likely to provide cardioprotection by blocking angiotensin II formation, we determined the effects of an angiotensin II type 1 (AT(1)) receptor blocker, losartan, and a bradykinin B(2) receptor blocker, HOE 140, on myocardial protection. Isolated rat hearts were perfused initially by the Langendorff mode with Krebs-Henseleit buffer (KHB) for 15 minutes in the absence (control) or presence of losartan (4.5 micromol/L) and/or HOE 140 (10 micromol/L). After conversion to the working mode for 10 minutes (baseline), randomly assigned control and experimental hearts were subjected to 30 minutes of normothermic global ischemia followed by 2 hours of reperfusion. Myocardial function, infarct size, cardiomyocyte apoptosis, and amount of bradykinin/angiotensin released from the hearts were measured at baseline and during reperfusion while in the working mode. Significant postischemic ventricular recovery was demonstrated by improved developed pressure and aortic flow and reduced myocardial infarct size and apoptotic cell death with losartan, whereas the reverse was true for HOE 140. The functional recovery and infarct size-lowering ability of losartan were partially blocked and the antiapoptotic function of losartan was completely blocked by HOE 140. CONCLUSIONS: The results document that losartan reduced whereas HOE 140 increased myocardial ischemia/reperfusion injury by blocking AT(1) and bradykinin B(2) receptors, respectively, suggesting a role of the bradykinin B(2) receptor in PC. Losartan provided cardioprotection through both bradykinin-dependent and bradykinin-independent mechanisms.